



ASX/AIM Announcement

30 September 2025

Wellnex Life Limited (ASX/AIM:WNX)

Audited FY25 Annual Report Chairman's Statement

- FY25 delivered strong top-line growth, with revenue increasing 40.5% on FY24 to A\$23.6 million underpinned by the first full-year contribution from Pain Away.
- Gross profit for the year was A\$6.9 million, representing 29.2% of total revenue.
- Performance in 1HFY25 was impacted by higher trade investment, resulting in a gross margin of 23%. However, margins recovered to 37% in 2HFY25 resulting from a more disciplined approach to trade investment.
- Net assets increased to A\$11.2 million at 30 June 2025, up from A\$6.1 million as at 30 June 2024.

Ash Vesali, Chairman of Wellnex said: “Financial year 25 saw management navigating both opportunities and challenges. The financial results reflect the reality of integration costs relating to the successful acquisition of Pain Away and one-off impacts, including the dual listing on the AIM Market of the London Stock Exchange. However, they also highlight the underlying strength of our brands and the significant opportunities ahead.

The business demonstrated progress in strengthening the balance sheet and establishing a stage for continued recovery and growth. The inclusion of Pain Away across a full year has been a positive driver, and the refinement of our trade investment strategy has begun to restore margin performance.

As recently appointed Chairman, I recognise the work that remains ahead of us to return the business to profitability. The Board collectively is committed to achieving our clear priorities, with disciplined execution of our refined strategy and continued focus on governance discipline to capitalise on the significant opportunities ahead. I look forward to communicating, as Chairman, on our performance further as we move forward. I thank all our shareholders for their continued support.”

WELLNEX

To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: <https://wellnexlife.investorportal.com.au/register/>

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

Zack Bozinovski
Chief Executive Officer & Managing Director
P: +61 3 8399 9419
E: zack.b@wellnexlife.com.au

Reach Markets

T: 1300 805 795
E: IR@reachmarkets.com.au

UK Investors

Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson

Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)
Sebastian Wykeham

swykeham@oranacorp.com

S.P. Angel Corporate Finance LLP (Joint Broker)
David Hignell / Vadim Alexandre

Tel: +44 (0)20 3470 0470